Last reviewed · How we verify

NCT04595396

Laparoscopic Gastric Bypass as Metabolic Surgery in Obesity Class 1

Completed Last updated 20 October 2020
What this trial tests

trial testing Laparoscopic Gastric Bypass in Type2 Diabetes in 51 participants. Completed in 31 December 2019.

Timeline
1 September 2012
Primary endpoint
1 January 2019
31 December 2019

Quick facts

Lead sponsorCARLOS ZERRWECK LOPEZ
StatusCompleted
Study typeOBSERVATIONAL
Enrollment51
Start date1 September 2012
Primary completion1 January 2019
Estimated completion31 December 2019
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

CARLOS ZERRWECK LOPEZ

Who can join

Adults 18 to 60, any sex, with Type2 Diabetes or Bariatric Surgery Candidate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective study including Mexican patients diagnosed with type 2 diabetes and class 1 obesity, undergoing laparoscopic gastric bypass. The objective was to determine short, mid-and long-term outcomes (weight loss, metabolic, morbidity and diabetes remission). A subanalysis was included, based on preoperative usage of one (Group A) or more antidiabetics ± insulin (Group B).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Metabolic Surgery and Class 1 Obesity (< 35 kg/m<sup>2</sup>): a Prospective Study with Short-, Mid-, and Long-term Results Among Latinos.
    Cevallos L, Rodríguez FM, Herrera A, Sepúlveda EM, et al · · 2021 · cited 5× · PMID 33598844 · DOI 10.1007/s11695-021-05275-3

Verify or expand the search:

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04595396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing